Loading
A phase 2 trial of Panobinostat in Hodgkin lymphoma, run by Novartis Pharmaceuticals, completed.
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT00742027 by Novartis Pharmaceuticals, with 129 participants recorded, started 2008-09-16 and reaching its primary completion in 2013-08-12. Interventions recorded: Panobinostat. Conditions recorded: Classical Hodgkin's Lymphoma.
Linked to the drug Panobinostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
129 enrolled.
range 0.7 to 53; Figures from the ClinicalTrials.gov results section (first posted 2021-06-03), not from a publication
Source95% CI 5.4 to 8.3; Figures from the ClinicalTrials.gov results section (first posted 2021-06-03), not from a publication
SourceShares Panobinostat, Novartis and the tag pipeline.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.